CARBONYLAMINO SUBSTITUTING ECYL PHENYL OF UREA DERIVATIVES, PROCEDURES FOR THEIR PRODUCTION AND THEIR USE

15-10-2009 дата публикации
Номер:
AT0000443697T
Принадлежит:
Контакты:
Номер заявки: 48-04-0470
Дата заявки: 07-01-2004

[1]

(19) AUSTRALIAN PATENT OFFICE (54) Title Carbonyl-amino substituted acyl phenyl urea derivatives, method for the production and use thereof (51 )6 International Patent Classification(s) CO7C 275/54A6IK 031/33 C07D 333/26 C07D 213/56 A61K 031/17 C07D 307/56 (21) Application No: (22) A (87) WIPONo: WO04/065356 (30) Priority Data (31) Number 103 02 452.2 (32) Date 2003.01.23 (33) Country DE (43) Publication Date : 2004.08.05 (71) Applicant(s) Aventis Pharma Deutschland GmbH (21) Application No: (22) A (87) WIPONo: WO04/065356 (30) Priority Data (31) Number 103 02 452.2 (32) Date 2003.01.23 (33) Country DE (43) Publication Date : 2004.08.05 (71) Applicant(s) Aventis Pharma Deutschland GmbH ation Date: 2004.01.07 (72) Inventor(s) Kadereit, Dieter; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich ; Von Roedern, Erich; Schoenafinger, Karl; Enhsen, Alfons; Defossa, Elisabeth (74) Agent/Attorney Watermark Patent & Trademark Attorneys, 290 Burv/ood Road, Hawthorn, VIC, 3122



[2]

The invention relates to compounds of formula (I) wherein the radicals have the cited meaning, in addition to the physiologically compatible salts thereof. The compounds, for example, can be used as medicaments for preventing and treating type 2 diabetes.



Compounds of the formula I in which R8, R9, R10, R11 are each independently H, F or Cl; R1, R2, R4, R6 are each H; R3, R5 are each independently H, Cl, OR12, COOR12, N(R13)(R14) or (C1-C6) -alkyl ; R7 is (C1-C6) -alkyl, where alkyl may be polysubstituted by F, OR12, COOR12 or N(R13)(R14), or is (C3-C6)-cycloalkyl, (C2-C6)- alkenyl, (C2-C6)-alkynyl, (C1-C5)-alkylcarboxy- (C1-C6) -alkylene, COOR12, phenyl, where phenyl may be polysubstituted by F, OMe or OCF3, or is benzyl whose phenyl ring may be substituted by OMe, pyridyl, thienyl, furanyl, indolylcarbonyl, benzofuranyl, where benzofuranyl may be substituted by Cl or OMe; R12 is H or (C1-C8) -alkyl, where alkyl may be polysubstituted by F; R13, R14 are each independently H or (C1-C8)-alkyl; and where R13 and R14, together with the nitrogen atom to which they are bonded, may form a 5-membered, saturated heterocyclic ring; excluding compounds of the formula I in which the radicals are at the same time defined as follows: R5 is halogen or unsubstituted (C1-C6)-alkyl, R7 is heterocyclic radical or heteroaryl; and their physiologically tolerated salts.

A pharmaceutical comprising one or more of the compounds as claimed in claim 1.

A pharmaceutical comprising one or more of the compounds as claimed in claim 1 and one or more blood sugar-reducing active ingredients.

A pharmaceutical comprising one or more of the compounds as claimed in claim 1 and one or more statins.

The use of the compounds as claimed in claim 1 for producing a medicament for treating type 2 diabetes.

The use of the compounds as claimed in claim 1 for producing a medicament for lowering blood sugar.

The use of the compounds as claimed in claim 1 in combination with at least one further blood sugar-reducing active ingredient for producing a medicament for treating type 2 diabetes.

The use of the compounds as claimed in claim 1 in combination with at least one further blood sugar-reducing active ingredient for producing a medicament for lowering blood sugar.

A process for producing a pharmaceutical comprising one or more of the compounds as claimed in claim 1, which comprises mixing the active ingredient with a pharmaceutically suitable carrier and bringing this mixture into a form which is suitable for administration.